<DOC>
	<DOC>NCT02850003</DOC>
	<brief_summary>Study designed to assess the safety and plasma PK of tretinoin and its metabolites from topically applied IDP-120 gel.</brief_summary>
	<brief_title>Absorption and Systematic Pharmacokinetics of Topically Applied IDP-120 Gel</brief_title>
	<detailed_description>An Open-label study designed to assess the safety and plasma PK of tretinoin and its metabolites from topically applied IDP-120 gel.</detailed_description>
	<criteria>Key Male or female between the ages of 9 and &lt;17 (16 years 11 months) Written and verbal informed consent must be obtained. Subjects less than age of consent must sign an assent for the study and a parent or legal guardian must sign the informed consent. Subject must have a score of 3 (moderate) or 4 (severe) on the Evaluator's Global Severity assessment. Subject with facial acne inflammatory lesion count no less than 20 but no more than 40. Subject with facial acne noninflammatory lesion count no less than 20 but no more than 100. Key Use of an investigational drug or device within 30 days of enrollment, previous participation in a research study with IDP120 Gel, or participation in a research study concurrent with this study. Any dermatological conditions on the face that could interfere with clinical evaluations such as acne conglobate, acne fulminans, secondary acne, perioral dermatitis, clinically significant rosacea, gramnegative folliculitis. Any underlying disease or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion counts inconclusive. Subjects with a facial beard or mustache that could interfere with the study assessments Subjects with more than 2 facial nodules.</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>